Related Experiment Video
Updated: May 21, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
[Limitations of anticoagulant therapy]
J Martí-Fàbregas1, R Delgado-Mederos, J Mateo
1Unidad de Enfermedades Vasculares Cerebrales, Servicio de Hematología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. jmarti@santpau.cat
Neurologia (Barcelona, Spain)
|June 12, 2012
Summary
Vitamin K antagonists prevent blood clots in patients with atrial fibrillation but carry a risk of bleeding. New oral anticoagulants are needed for safer, more effective clot prevention.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Context:
- Vitamin K antagonists (VKAs) are established treatments for preventing emboli in cardiac conditions like atrial fibrillation.
- Secondary prevention shows greater stroke risk reduction but increases risk of serious hemorrhagic complications, including cerebral hemorrhage.
Purpose:
- To review the efficacy and risks associated with Vitamin K antagonists in preventing embolic events.
- To highlight the need for novel oral anticoagulants with improved safety and efficacy profiles.
Summary:
- VKAs effectively reduce stroke risk, particularly in secondary prevention, but require careful management due to a narrow therapeutic window (INR 2-3) and significant bleeding risks.
- Treatment variability necessitates frequent monitoring, underscoring the limitations of current anticoagulant therapies.
- The development of new oral anticoagulants is crucial for enhancing patient safety and treatment effectiveness.
Impact:
- Improved patient outcomes through safer and more effective anticoagulation strategies.
- Potential reduction in the incidence of stroke and other embolic events.
- Advancement in the management of thromboembolic disorders in patients with cardiac conditions.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.